Efficacy and Safety of Innate and Adaptive Immunotherapy Combined with Standard of Care in High-grade Gliomas: a Systematic Review and Meta-analysis

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Jul 24

PMID 37483593

Authors

Baofeng Guo

Shengnan Zhang

Libo Xu

Jicheng Sun

Wai-Lun Chan

Pengfei Zheng

Jinnan Zhang

Ling Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Malignant glioma is the most common intracranial malignant tumor with the highest mortality. In the era of immunotherapy, it is important to determine what type of immunotherapy provides the best chance of survival.

Method: Here, the efficacy and safety of immunotherapy in high-grade glioma (HGG) were evaluated by systematic review and meta-analysis. The differences between various types of immunotherapy were explored. Retrieved hits were screened for inclusion in 2,317 articles. We extracted the overall survival (OS) and progression-free survival (PFS) hazard ratios (HRs) as two key outcomes for examining the efficacy of immunotherapy. We also analyzed data on the reported corresponding adverse events to assess the safety of immunotherapy. This study was registered with PROSPERO (CRD42019112356).

Results: We included a total of 1,271 patients, of which 524 received a combination of immunotherapy and standard of care (SOC), while 747 received SOC alone. We found that immunotherapy extended the OS (HR = 0.74; 95% confidence interval [CI], 0.56-0.99; = -2.00, = 0.0458 < 0.05) and PFS (HR = 0.67; 95% CI, 0.45-0.99; = -1.99, = 0.0466 < 0.05), although certain adverse events occurred (proportion = 0.0773, 95% CI, 0.0589-0.1014). Our data have demonstrated the efficacy of the dendritic cell (DC) vaccine in prolonging the OS (HR = 0.38; 95% CI, 0.21-0.68; Z = -3.23; = 0.0012 < 0.05) of glioma patients. Oncolytic viral therapy (VT) only extended patient survival in a subgroup analysis (HR = 0.60; 95% CI, 0.45-0.80; = -3.53; = 0.0004 < 0.05). By contrast, immunopotentiation (IP) did not prolong OS (HR = 0.69; 95% CI, 0.50-0.96; = -2.23; = 0.0256).

Conclusion: Thus, DC vaccination significantly prolonged the OS of HGG patients, however, the efficacy of VT and IP should be explored in further studies. All the therapeutic schemes evaluated were associated with certain side effects.

Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=112356.

Citing Articles

Is add-on Bevacizumab therapy to Temozolomide and radiotherapy associated with clinical utility for newly diagnosed Glioblastoma? A systematic review and meta-analysis.

Habibi M, Shad N, Mirjnani M, Fasihi S, Sadeghi S, Karami S Neurosurg Rev. 2024; 47(1):445.

PMID: 39162874 DOI: 10.1007/s10143-024-02667-8.

References

Wheeler L, Manzanera A, Bell S, Cavaliere R, McGregor J, Grecula J . Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma. Neuro Oncol. 2016; 18(8):1137-45. PMC: 4933478. DOI: 10.1093/neuonc/now002. View

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Response to: Practical methods for incorporating summary time-to-event data into meta. Authors' reply. Trials. 2014; 14:391. View

Tauriello D, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M . TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018; 554(7693):538-543. DOI: 10.1038/nature25492. View

Lv L, Huang J, Xi H, Zhou X . Efficacy and safety of dendritic cell vaccines for patients with glioblastoma: A meta-analysis of randomized controlled trials. Int Immunopharmacol. 2020; 83:106336. DOI: 10.1016/j.intimp.2020.106336. View

Shen S, Woroniecka K, Barbour A, Fecci P, Sanchez-Perez L, Sampson J . CAR T cells and checkpoint inhibition for the treatment of glioblastoma. Expert Opin Biol Ther. 2020; 20(6):579-591. PMC: 7202971. DOI: 10.1080/14712598.2020.1727436. View

Louis D, Perry A, Wesseling P, Brat D, Cree I, Figarella-Branger D . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8):1231-1251. PMC: 8328013. DOI: 10.1093/neuonc/noab106. View

Desjardins A, Gromeier M, Herndon 2nd J, Beaubier N, Bolognesi D, Friedman A . Recurrent Glioblastoma Treated with Recombinant Poliovirus. N Engl J Med. 2018; 379(2):150-161. PMC: 6065102. DOI: 10.1056/NEJMoa1716435. View

Pekmezci M, Perry A . Practical molecular pathologic diagnosis of infiltrating gliomas. Surg Pathol Clin. 2015; 8(1):49-61. DOI: 10.1016/j.path.2014.10.004. View

Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J . Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial. Nat Med. 2022; 28(8):1630-1639. PMC: 9388376. DOI: 10.1038/s41591-022-01897-x. View

10.

Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D . HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017; 3(8):1094-1101. PMC: 5747970. DOI: 10.1001/jamaoncol.2017.0184. View

11.

Weigel B, Rodeberg D, Krieg A, Blazar B . CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res. 2003; 9(8):3105-14. View

12.

Ji N, Weng D, Liu C, Gu Z, Chen S, Guo Y . Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma. Oncotarget. 2015; 7(4):4369-78. PMC: 4826211. DOI: 10.18632/oncotarget.6737. View

13.

Lim M, Xia Y, Bettegowda C, Weller M . Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2018; 15(7):422-442. DOI: 10.1038/s41571-018-0003-5. View

14.

Brown C, Alizadeh D, Starr R, Weng L, Wagner J, Naranjo A . Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med. 2016; 375(26):2561-9. PMC: 5390684. DOI: 10.1056/NEJMoa1610497. View

15.

Bernstock J, Hoffman S, Kappel A, Valdes P, Essayed W, Klinger N . Immunotherapy approaches for the treatment of diffuse midline gliomas. Oncoimmunology. 2022; 11(1):2124058. PMC: 9519005. DOI: 10.1080/2162402X.2022.2124058. View

16.

Yao Y, Luo F, Tang C, Chen D, Qin Z, Hua W . Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial. Cancer Immunol Immunother. 2018; 67(11):1777-1788. PMC: 11028057. DOI: 10.1007/s00262-018-2232-y. View

17.

Artene S, Turcu-Stiolica A, Ciurea M, Folcuti C, Tataranu L, Alexandru O . Comparative effect of immunotherapy and standard therapy in patients with high grade glioma: a meta-analysis of published clinical trials. Sci Rep. 2018; 8(1):11800. PMC: 6081409. DOI: 10.1038/s41598-018-30296-x. View

18.

Reardon D, Brandes A, Omuro A, Mulholland P, Lim M, Wick A . Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6(7):1003-1010. PMC: 7243167. DOI: 10.1001/jamaoncol.2020.1024. View

19.

Westphal M, Yla-Herttuala S, Martin J, Warnke P, Menei P, Eckland D . Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013; 14(9):823-33. DOI: 10.1016/S1470-2045(13)70274-2. View

20.

Wang D, Aguilar B, Starr R, Alizadeh D, Brito A, Sarkissian A . Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity. JCI Insight. 2018; 3(10). PMC: 6012522. DOI: 10.1172/jci.insight.99048. View